Ceralasertib
Ceralasertib is an oral ATR kinase inhibitor that targets the DNA-damage response in cancer cells. AstraZeneca evaluated it in combination with the checkpoint inhibitor durvalumab in previously treated NSCLC (the LATIFY study).
Also known as: AZD6738
Ceralasertib forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Ceralasertib
What is Ceralasertib?
Ceralasertib is an oral ATR kinase inhibitor that targets the DNA-damage response in cancer cells. AstraZeneca evaluated it in combination with the checkpoint inhibitor durvalumab in previously treated NSCLC (the LATIFY study). It is a oral atr kinase inhibitor developed by AstraZeneca.
What does Ceralasertib target?
Ceralasertib acts on ATR kinase.
How well do AI models predict Ceralasertib trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.